RecruitingPhase 1Phase 2NCT07531745
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients With Dravet Syndrome
Sponsor
Ionis Pharmaceuticals, Inc.
Enrollment
32 participants
Start Date
Apr 1, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The primary purpose of this study is to evaluate the safety and tolerability of ION337 in participants with Dravet syndrome (DS).
Eligibility
Min Age: 2 YearsMax Age: 12 Years
Inclusion Criteria7
- Participant is aged ≥ 2 to ≤ 12 years old at the time of informed consent.
- Participant has at least 1 parent or caregiver ≥ 18 years old who is willing and able to provide informed consent (signed and dated) and attend all scheduled study visits.
- Has a documented diagnosis of DS according to the International League Against Epilepsy (ILAE) criteria and as agreed by the Epilepsy Study Consortium, Inc (ESCI).
- Has confirmation of a pathogenic or likely pathogenic SCN1A variant.
- Must be currently receiving ≥ 1 concomitant ASM at a stable dose/regimen for ≥ 4 weeks prior to informed consent.
- Must have all other interventions for epilepsy (including ketogenic diet or VNS) as well as any other concomitant medications including medications for behavioral management, sleep, and supplements or nutritional support stable for ≥ 4 weeks prior to informed consent. Vagus nerve stimulator implantation must have occurred ≥ 6 months prior to informed consent.
- Experiences the required number of major motor seizures during the Screening Period.
Exclusion Criteria6
- Known brain or spinal disease that would interfere with the LP procedure or CSF circulation, or presence of other factors that would affect the safety of the LP procedure.
- Pathogenic or likely pathogenic variant in another gene that causes epilepsy.
- Has had prior treatment with or is currently enrolled in an interventional clinical trial for a gene therapy or for another antisense oligonucleotide (ASO) for the treatment of DS.
- Has had treatment with or is currently enrolled in an interventional clinical trial of any other investigational drug, biological agent, or device within 30 days prior to Screening, or 5 half-lives of investigational agent, whichever is longer.
- Current treatment with an anti-seizure medication (ASM) acting primarily as a sodium channel blocker, as maintenance treatment.
- Prior brain surgeries including: corpus callosotomy, implantation of device for deep brain stimulation or any other palliative brain surgery intended to reduce seizure burden.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGION337
ION337 will be administered by ITB injection.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07531745
Related Trials
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
NCT0541949210 locations
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT0666039497 locations
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT0687212561 locations
Multicentre Real-life Follow-up Study of Rare Epileptic Syndromes in Children and Adolescents
NCT0512691411 locations
Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY
NCT0548583118 locations